Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avadomide - Celgene Corporation

Drug Profile

Avadomide - Celgene Corporation

Alternative Names: CC 122

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; H. Lee Moffitt Cancer Center and Research Institute; Juno Therapeutics
  • Class Antineoplastics; Piperidones; Quinazolines
  • Mechanism of Action CRBN protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Liver cancer; Non-Hodgkin's lymphoma
  • Phase I Solid tumours
  • No development reported Glioblastoma; Multiple myeloma

Most Recent Events

  • 12 Dec 2023 Celgene terminates a phase I trial in Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada, Italy, USA and France (PO) as the trial was replaced with another clinical trial (NCT02031419)
  • 21 Nov 2023 Celgene Corporation completes a phase I trial in Glioblastoma, Non-Hodgkin's lymphoma, Multiple myeloma and Solid tumours in USA, Belgium, Italy, France and Spain (PO) (NCT01421524)
  • 28 Sep 2023 Celgene Corporation plans a phase Ib trial for Diffuse large B-cell lymphoma and Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in Italy, the Netherlands and France (NCT02417285) (Eudra CT 2014-003333-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top